Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research report sent to investors on Monday, MarketBeat.com reports. The brokerage issued an outperform rating and a $19.00 price target on the biopharmaceutical company's stock.

A number of other research firms have also commented on ABEO. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Stifel Nicolaus reduced their target price on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Finally, HC Wainwright upped their target price on Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.25.

Abeona Therapeutics Trading Down 0.2%

Shares of NASDAQ ABEO traded down $0.01 during midday trading on Monday, reaching $6.27. The company had a trading volume of 907,831 shares, compared to its average volume of 633,383. Abeona Therapeutics has a one year low of $3.93 and a one year high of $7.32. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm's fifty day moving average price is $5.42 and its 200-day moving average price is $5.56. The stock has a market cap of $320.75 million, a PE ratio of -2.33 and a beta of 1.68.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.11. On average, equities research analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Mark Alvino sold 8,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the sale, the director now owns 92,435 shares in the company, valued at $525,030.80. This represents a 7.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares in the company, valued at $6,478,439.16. The trade was a 1.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock worth $177,700 in the last 90 days. Insiders own 6.90% of the company's stock.

Institutional Trading of Abeona Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. OMERS ADMINISTRATION Corp boosted its stake in Abeona Therapeutics by 11.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock valued at $344,000 after purchasing an additional 7,155 shares during the last quarter. Twinbeech Capital LP purchased a new stake in Abeona Therapeutics during the 4th quarter valued at $58,000. Northern Trust Corp grew its holdings in shares of Abeona Therapeutics by 6.6% in the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock worth $1,030,000 after acquiring an additional 11,478 shares during the period. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics during the fourth quarter valued at about $67,000. Finally, Cannon Global Investment Management LLC bought a new stake in Abeona Therapeutics during the first quarter valued at about $67,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.